
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39289424
72174
10.1038/s41598-024-72174-9
Article
Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer
Murakami Yuichi y-murakami@st-mary-med.or.jp

1
Katsuchi Daisuke 1
Matsumoto Taichi 1
Kanazawa Kuon 1
Shibata Tomohiro 2
Kawahara Akihiko 3
Akiba Jun 3
Yanaihara Nozomu 4
Okamoto Aikou 4
Itamochi Hiroaki 5
Sugiyama Toru 6
Terada Atsumu 6
Nishio Shin 7
Tsuda Naotake 7
Kato Kiyoko 8
Ono Mayumi 1
Kuwano Michihiko 1
1 Basic Medical Research Unit, St. Mary’s Research Center, 422 Tsubukuhon-Machi, Kurume, Fukuoka, 830-8543 Japan
2 https://ror.org/02pammg90 grid.50956.3f 0000 0001 2152 9905 Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048 USA
3 https://ror.org/00vjxjf30 grid.470127.7 0000 0004 1760 3449 Department of Diagnostic Pathology, Kurume University Hospital, Kurume, 830-0011 Japan
4 https://ror.org/039ygjf22 grid.411898.d 0000 0001 0661 2073 Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, 105-8461 Japan
5 https://ror.org/04cybtr86 grid.411790.a 0000 0000 9613 6383 Department of Clinical Oncology, Iwate Medical University School of Medicine, Yahaba-Cho, 028-3694 Japan
6 grid.416532.7 0000 0004 0569 9156 Department of Obstetrics and Gynecology, St. Mary’s Hospital, Kurume, 830-8543 Japan
7 https://ror.org/057xtrt18 grid.410781.b 0000 0001 0706 0776 Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, 830-0011 Japan
8 https://ror.org/00p4k0j84 grid.177174.3 0000 0001 2242 4849 Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582 Japan
17 9 2024
17 9 2024
2024
14 2170116 5 2024
4 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Y-box binding protein 1 (YBX1) promotes oncogenic transformation and tumor growth. YBX1 plays a role in regulation of cell cycle promotion via upregulation of cell cycle-related genes. In ovarian cancer, YBX1 also promotes tumor growth, but the mechanisms of YBX1 in cell growth and cell cycle in ovarian cancer remain not to be fully understood. Here, we investigated whether YBX1-dependent cancer cell proliferation was specifically associated with expression of cell cycle related genes in ovarian cancer. Protein and mRNA expression levels of YBX1 and cell cycle-related genes in ovarian cancer cell lines and tissues were determined by western blot analysis, immunohistochemical analysis and reverse transcription-quantitative PCR. Cell cycle analysis was performed by flow cytometry. Luciferase assay and Chromatin immunoprecipitation assay were used to investigate a transcriptional function of YBX1. YBX1 silencing induced marked growth suppression in 4 cell lines (group A), moderate suppression in 5 cell lines (group B), and no suppression in 3 cell lines (group C) among 12 ovarian cancer cell lines in culture. The YBX1 silencing induced cell cycle arrest at G2/M phase and suppressed expression of cyclin A1 gene in group A and B cell lines, but not in group C cell lines. Cyclin A1 silencing specifically suppressed cell proliferation in group A cell lines and partially in group B cell lines, but not at all in group C cell lines. YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1.

Keywords

YBX1
Cyclin A1
Cell cycle
G2/M arrest
Ovarian cancer
Subject terms

Ovarian cancer
Cell growth
Japan Society for the Promotion of Science24K09909 Murakami Yuichi issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The cell cycle is precisely controlled by cyclin-dependent kinases, cyclins, and checkpoint regulators in normal cells. However, in cancer cells, the cell cycle is frequently altered by mutations in genes involved in the cell cycle, and promising cancer therapeutic drugs targeting cell cycle-related proteins have recently been developed1,2. Ovarian cancer shows abnormalities in cell cycle-related genes, including mutations in CDKN2A, overexpression of cyclin D1, and mutations in Rb. CDK4 and CDK6 inhibitors that target the cell cycle are currently in clinical use for the treatment of patients with estrogen receptor-positive metastatic breast cancer. These agents, alone or in combination with other agents, are being tested in ovarian cancer3. More than 70% of ovarian cancer cases are identified as either high-grade serous adenocarcinoma (HGSC) or ovarian clear cell carcinoma (OCCC). Bai and colleagues recently reported that approximately 20% of HGSC cases exhibit cyclin E gene amplification and often show resistance to chemotherapeutics4.

Y-box binding protein 1 (YBX1) is an ancestral DNA/RNA binding oncoprotein containing a cold shock domain. It is involved in the regulation of transcription, translation, DNA damage repair, and various other biological processes. YBX1 protein is mainly localized in the cytoplasm, but some is also found in the nucleus. In the nucleus, YBX1 is crucial for transcriptional regulation through the Y-box (inverted CCAAT box)5, while in the cytoplasm, it is responsible for mRNA stability and translation6. YBX1 promotes cancer cell growth, tumorigenesis, and malignant progression in various human malignancies including breast cancer, prostate cancer, and colorectal cancer5,7–11, and enhances the expression of genes that mediate the cell cycle, cell growth, and drug resistance in cancer cells12–18. Regarding its role in cell cycle promotion, YBX1 facilitates cell cycle progression at G1/S19–24 and G2/M phases25,26 by augmenting the expression of various genes involved in the transition from G1 to S and/or from G2 to M, such as cyclin A2, cyclin B, cyclin D, cyclin E, CDC6, CDC20, and CDKN1A, at the transcriptional and/or post-transcriptional levels15,16,27.

Previous studies have reported that enhanced expression of YBX1 is closely correlated with poor outcomes and drug resistance in ovarian tumors28–30. Drug resistance to paclitaxel and cisplatin was induced by increasing YBX1 expression in ovarian cancer31,32. Furthermore, co-expression of cyclin A with YBX1 is associated with resistance to platinum-based chemotherapy and poor outcomes in ovarian cancer33. Additionally, YBX1-mediated promotion of cell growth through activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated protein kinase (ERK)/p90 ribosomal S6 kinase (RSK) and/or phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathways contributes to poor outcomes in patients with ovarian cancer34. Co-expression of YBX1 and cyclin B also contributes to chemoresistance in ovarian cancer13. Collectively, these findings suggest that targeting YBX1 and related genes may provide an effective strategy for treating ovarian cancer35 as well as other malignancies in women27,36.

Here, we investigated the mechanisms underlying distinct growth-suppressive effects of YBX1 downregulation in various cell lines. Furthermore, we have examined whether the expression levels of any cell cycle-related genes are specifically associated with YBX1-driven cell growth; analysis of this pathway may contribute to improving our understanding of the roles of YBX1 in oncogenic transformation and tumor growth. Accordingly, in the current study, we assessed whether cancer cell growth driven by YBX1 was closely associated with any specific cell cycle phase transition, and also with the expression of cyclin A, cyclin B, cyclin D, cyclin E, CDC6, and CDC20 genes.

Materials and methods

Patient characteristics

From 2007 to 2019, 101 patients with histologically proven cancer were treated at the Department of Obstetrics and Gynecology, Kyushu University (n = 62) and the Department of Obstetrics and Gynecology, The Jikei University School of Medicine (n = 39). This study was approved by the institutional review board at each hospital (Kyushu University, # 622-00; The Jikei University School of Medicine, 32–379 (10467)). This study conforms to the principles of the Declaration of Helsinki, and informed consent was obtained from all patients. Patient demographics are summarized in Supplementary Table S1.

Cell culture

TOV-21G, TOV-112D, OVCAR-3, and SK-OV-3 cells were purchased from American Type Culture Collection (Manassas, VA, USA). OVSAHO cells (JCRB1046) were purchased from Japanese Collection of Research Bioresources (Osaka, Japan). ES2, JHOC-5, and MCAS cells were kindly provided by Dr. Kiyoko Kato (Department of Obstetrics and Gynecology, Kyushu University). OVISE, OVMANA, OVTOKO, and KOC-7C cells were kindly provided by Dr. Hiroaki Itamochi (Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine). JHOC-5, OVTOKO, TOV-21G, KOC-7C, OVISE, and OVMANA cells were derived from OCCC; ES2, OVCAR3, SK-OV-3, and OVSAHO cells were derived from HGSC; MCAS cells were derived from mucinous cystadenocarcinoma; and TOV-112D cells were derived from endometrial carcinoma. JHOC-5 cells were maintained in Dulbecco’s modified Eagle medium (DMEM)/F12 (cat. no. 11320–033; Thermo Fisher Scientific Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) and 0.1 mM MEM nonessential amino acid solution (Thermo Fisher Scientific Inc., MA, USA). KOC-7C cells were maintained in DMEM (cat. no. #05919; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% FBS. TOV-21G, TOV-112D, OVCAR-3, SK-OV-3, OVSAHO, ES2, MCAS, OVISE, OVMANA, and OVTOKO cells were maintained in RPMI (cat. no. #05918; Nissui Pharmaceutical Co., Ltd.) supplemented with 10% FBS. All cell lines were maintained in an atmosphere of 5% CO2 and passaged for 6 months or less. The cell lines were not further tested or authenticated by the investigators. In the current study, we classified the ovarian cancer cell lines into three groups based on the inhibitory effect of YBX1 siRNA treatment on cell growth for 5 days. Group A includes cells with more than 50% inhibition, group B includes cells with 50% to 10% inhibition, and group C includes cells with less than 10% inhibition. ES2, JHOC-5, MCAS, and OVTOKO cells are in group A, OVCAR3, TOV-112D, TOV-21G, SK-OV-3, and KOC-7C cells are in group B, and OVSAHO, OVISE, and OVMANA cells are in group C.

Cell proliferation assay

All cell lines were seeded at 5–10 × 103 cells/well in 24-well plates and counted using a CDA-1000 particle counter (Sysmex Corporation, Hyogo, Japan) at 1, 3, and 5 days after small interfering RNA (siRNA) transfection. Results are expressed as means ± standard deviations of triplicate wells.

Reagents

Antibodies against p-YBX1 (cat. no. #2900), cyclin A2 (cat. no. #67955), cyclin B1 (cat. no. #4138), cyclin D1 (cat. no. #55506), cyclin E (cat. no. #4129), and CDC6 (cat. no. #3387), PKCα (cat. no. #59754), p-PKCα/β II (cat. no. #9375), AKT (cat. no. #9272) p-AKT (cat. no. #4060), and CREB (cat. no. #9197) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against YBX1 (cat. no. ab76149), cyclin A1 (cat. no. ab270940), and β-actin (cat. no. ab8227) were purchased from Abcam (Cambridge, UK). Antibodies against α-tubulin (cat. no. T6074) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against CDC20 (cat. no. NB100-59828) were purchased from Novus Biologicals (Centennial, CO, USA). Antibodies against GAPDH (cat. no. 2275-pc100) were purchased from Trevigen (Gaithersburg, MD, USA).

Transfection of siRNA

RNA-interference assays were performed using siRNA. The siRNAs corresponding to the nucleotide sequences of YBX1 (s9732 and s9731), CCNA1 (s17021), and CCNA2 (s2512) were purchased from Thermo Fisher Scientific. Cells were transfected with siRNA duplexes using Lipofectamine RNAiMAX and Opti-MEM (cat. no. 31985–070; Thermo Fisher Scientific Inc.) according to the manufacturer’s recommendations. As a negative control, cells transfected with Stealth RNAi siRNA Negative Control (cat. no. 12935300) were used.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated from human ovarian tumor tissue or ovarian cancer cell lines using ISOGEN (cat. no. 311–02501; Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer’s instructions. The RNA concentration was assessed by spectrophotometry at 260 nm using NanoDrop 1000 (Thermo Fisher Scientific Inc.). The sets of primers and TaqMan probes for YBX1 (Hs00358903_g1), cyclin A1 (Hs00171105_m1), cyclin A2 (Hs00996788_m1), cyclin B1 (Hs00259126_m1), cyclin D1 (Hs00277039_m1), cyclin E1 (Hs01026536_m1), CDC6 (Hs00154374_m1), CDC20 (Hs00426680_mH), and RNA18S5 (Hs03928985_g1) were purchased from Thermo Fisher Scientific. RT-qPCR was performed using iTaq Universal Probes One-Step Kit (cat. no. 1725141; Bio-Rad Laboratories, Hercules, CA, USA) in a CFX Connect Real-Time PCR Detection System (cat. no. 1855201J1; Bio-Rad Laboratories). Each 10 µL reaction mix contained 20 ng extracted RNA, 5 µL 2 × iTaq PCR reaction mix, 0.25 µL iScript reverse transcriptase, and 0.5 µL 20 × primer and probes. The thermal cycling conditions were as follows: 50 °C for 10 min and 95˚C for 3 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 15 s. The expression of cell cycle-related genes was presented as relative ratios calculated using the ΔΔCq method37. mRNA data were normalized to RNA18S5.

Luciferase assay

Cells were seeded into 12-well plates, and the next day, cells were transfected with reporter vector (400 ng), phRL-TK vector (50 ng), and siRNA (6 µM) using Lipofectamine LTX reagent (cat. no. 15338–100; Thermo Fisher Scientific Inc.) according to the manufacturer's instructions. Firefly and Renilla luciferase activities were measured 48 h after transfection using the Dual-luciferase reporter assay system (cat. no. E1910; Promega, Madison, WI, USA). The firefly luciferase activity was normalized to Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP) assay

ChIP assay was performed as described previously38. Briefly, cells were fixed with formaldehyde, achieving a final concentration of 1%, and subsequently decrosslinked by 125 mM glycine. The cells were then lysed in SDS lysis buffer (50 mmol/L Tris–HCl, 10 mmol/L EDTA, 1% SDS, 1 mmol/L phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mmol/L sodium orthovanadate) and sonicated. The soluble chromatin was incubated with 2 µg anti-YB-1 antibody or IgG antibody, and immunoprecipitated. The immunoprecipitated DNA was treated with RNase A and proteinase K, followed by purification using the Qiaquick PCR purification kit (cat. no. 28106; QIAGEN, Hilden, Germany). Purified DNA was dissolved in 50 µl H2O, and 1 µl DNA was used for PCR analysis with GoTaq Green Master mix (cat. no. M7128; Promega) and the following primer pairs: CyclinA1#1, 5′-GGCTTGTCAGTCACCTATGC-3′ (forward) and 5′-GCAGAGGAGATGTGGGGATT-3′ (reverse); CyclinA1#2, 5′-AAACAGTCCCTTCCAAAGCC-3′ (forward) and 5′-GACCTGCTCACCTGACTCG-3′ (reverse). The thermal cycling conditions were as follows: 95 °C for 2 min, followed by 35 cycles at 95 °C for 30 s, 56 °C for 30 s, and 72 ˚C for 30 s, with a final extension at 72 °C for 5 min. PCR products were analyzed on 3% agarose gels and stained with ethidium bromide.

The cancer genome atlas (TCGA) dataset

TCGA data included a cohort of 316 patients with serous ovarian cancer obtained from the cBioPortal for Cancer Genomics (http://www.cbioportal.org)39. Using Spearman’s rank correlation coefficient, we examined the positive and negative associations between YBX1-correlated genes. In addition, by ranking genes in order of Spearman’s rank correlation coefficients for associations between YBX1 and those genes, the importance of the association between YBX1 and those genes was investigated.

Cell cycle analysis

For cell cycle analysis, cells were seeded in 60 mm dishes, incubated for 3 days, and then treated with 2 nM siRNAs for 3 days. Cell cycle analysis was conducted using a BD Pharmingen FITC BrdU Flow Kit (cat. no. 559619; BD Biosciences, San Jose, CA, USA) according to the manufacturer’s instructions, and cell cycle distribution was determined using a FACS-Calibur instrument (cat. no. 342973; BD Biosciences).

Subcellular protein fractionation

Subcellular fractionation was performed according to the manufacturer’s instructions using the Subcellular Protein Fractionation Kit for Cultured Cells (cat. no. 78840; Thermo Fisher Scientific Inc.).

Statistical analysis

Experimental results were expressed as mean ± SD. All calculations (Student's t tests, Mann–Whitney U tests and Pearson correlation coefficients) were done using GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA) and Microsoft Excel software. A P value of less than 0.05 was considered significant.

Results

YBX1 silencing suppressed the growth of some ovarian cancer cell lines in vitro

Enhanced YBX1 expression predicts poor outcomes in patients with various tumors including ovarian cancer15,16,27,28. In this study, we found that higher YBX1 mRNA expression was correlated with shorter survival periods in patients with HGSC based on the Kaplan–Meier plotter database (Fig. 1A) and GEO datasets (GDS3297; Fig. 1B). Therefore, we investigated the role of YBX1 in the proliferation of ovarian cancer cells in culture. Among 12 ovarian cancer cell lines, doubling times varied from 18 to 60 h (Supplementary Figure S1). The cells harbored various mutations in PIK3CA, PTEN, KRAS, BRAF, ARID1A, TP53, and BRCA1/2 genes, and the cyclin E gene was also amplified in OVCAR3 cells40. Western blot analysis demonstrated that the expression and phosphorylation of YBX1 also varied among the ovarian cancer cell lines (Fig. 1C). We next assessed whether silencing of YBX1 using siRNA could influence the growth rates of the 12 cell lines, finding that YBX1 silencing reduced the growth rate in some cells. YBX1 protein and mRNA levels were almost completely reduced in all cell lines after transfection with YBX1 siRNA#1 (Fig. 1D and Supplementary Figure S2). Figure 1E shows cell growth rates on days 1, 3, and 5 after transfection with or without YBX1 siRNA#1. ES2, JHOC-5, MCAS, and OVTOKO cell lines showed either almost complete growth suppression or non-logarithmic growth when YBX1 was silenced. OVCAR3, TOV-112D, TOV-21G, SK-OV-3, and KOC-7C cell lines showed reduced but still logarithmic growth as compared with the control following YBX1 siRNA transfection. Furthermore, OVSAHO, OVISE, and OVMANA cell lines showed no growth suppression following YBX1 siRNA transfection. Figure 1F summarizes the effects of YBX1 silencing on the cell growth suppression rate. We classified ovarian cancer cell lines into three groups based on the effect of YBX1 siRNA treatment on cell growth. Group A cell lines (ES2, JHOC-5, MCAS, and OVTOKO) showed more than 50% inhibition of cell proliferation compared to controls, while group B cell lines (OVCAR3, TOV-112D, TOV-21G, SK-OV-3, and KOC-7C) showed a weaker than group A but more than 10% inhibition of cell proliferation. On the other hand, cell lines of group C (OVSAHO, OVISE, and OVMANA) showed less than 10% inhibition after 5 days.Fig. 1 Growth inhibition in ovarian cancer cell lines following transfection with YBX1 siRNA#1. (A) Kaplan–Meier analysis of patients with HGSC showing high and low expression of YBX1 (Kaplan–Meier plotter database). (B) Comparison of 5-year survival rates in patients with HGSC showing high and low expression of YBX1 mRNA (GEO dataset accession no. GDS3297). **p = 0.00165. (C) Expression levels of YBX1 in 12 cell lines, as assessed by western blot analysis. (D) Western blot analysis showed that treatment with YBX1 siRNA#1 for 3 days inhibited the expression of YBX1 in all cell lines. (E–F) Cell growth was examined on days 1, 3, and 5 after transfection with YBX1 siRNA#1 (E). Based on cell growth inhibition levels after transfection with siRNA#1 for 5 days, the 12 cell lines were classified into 3 groups: marked inhibition (group A), moderate inhibition (group B), and no inhibition (group C) (F). Student’s t-tests were used to compare differences between groups. ∗p < 0.05; ∗∗p < 0.01. Data were represented as mean ± standard deviation for 3 independent experiments. Black, control siRNA; gray, YBX1 siRNA#1.

We next investigated whether the dependence of cell proliferation on YBX1 affects drug sensitivity to cisplatin, paclitaxel, and SU056, a YBX1 inhibitor (Supplementary Table S2). Almost all cell lines of groups A, B, and C showed similar sensitivity to cisplatin. Paclitaxel sensitivity was similar for these cell lines except for OVTOKO (group A) and KOC-7C (group B). KOC-7C showed much less sensitivity to paclitaxel (0.37 µmol/L). There was no correlation between sensitivity to cisplatin or paclitaxel and YBX1-dependent proliferation. On the other hand, OVSAHO and OVMANA cell lines of group C and KOC-7C of group B were less sensitive to SU056 than all group A cell lines and two group B cell lines. Cell lines with YBX1-dependent proliferation were more sensitive to SU056, indicating that YBX1-dependent proliferation is associated with drug sensitivity.

PKCα is highly expressed in cells that are dependent on YBX1 for proliferation

RPPA (Reverse Phase Protein Array) data from the MD Anderson Cell Lines Project (MCLP) showed that PKCα expression was higher in ES2 and OVTOKO in group A than in OVSAHO, OVISE and OVMANA in group C (Supplementary Table S3)41. Previous studies have reported that YBX1 is phosphorylated by PKCα and phosphorylation of YBX1 induces its translocation to the nucleus27,42. Consistent with RPPA data, we confirmed higher expression and phosphorylation of PKCα in group A and B cell lines than in group C cell lines (Supplementary Figure S3A). The pPKCα/PKCα ratios were also lower in OVCAR3 and KOC-7C in group B and three cell lines in group C. However, nuclear YBX1 was expressed at similar levels in both group A and group C cell lines (Supplementary Figure S3B). These results suggest that PKCα is highly expressed in group A cells, but is not associated with nuclear translocation of YBX1.

YBX1 silencing induced cell cycle arrest at G2/M and in part at G1/S

In Fig. 1, YBX1 silencing reduced cell proliferation, predicting and alteration in cell cycle regulation. We next performed FACS analysis for cell cycle tracing after transfection of the 12 ovarian cancer cell lines with YBX1 siRNA#1. FACS analysis (Supplementary Figure S4) showing the distribution of all cell lines in G0/G1, S, and G2/M phases is presented in Fig. 2A, B, and C, respectively. All 4 cell lines in group A and 1 cell line in group B significantly showed G2/M arrest when transfected with YBX1 siRNA#1, and 3 of the 9 cell lines in groups A and B showed reduced cell populations in S phase. By contrast, no cell cycle arrest was observed when group C cell lines were transfected with YBX1 siRNA#1.Fig. 2 Effects of YBX1 siRNA#1 on the cell cycle. (A–C) Percentages of cells in G0/G1 (A), S (B), and G2/M (C) phases following transfection with YBX1 siRNA #1 for 3 days. The percentages were determined by gating the FACS plot (Supplementary Figure S4). Student’s t-tests were used to compare differences between control siRNA and YBX1 siRNA#1 transfection. *p < 0.05; **p < 0.01. Error bars indicate standard deviations for 3 independent experiments.

Expression of cyclin A1 is highly influenced by YBX1 silencing in ovarian cancer cell lines

Some cell cycle-related genes were previously reported to be well correlated with YBX1 in various cancer cell lines15,16,27. Therefore, we examined whether cyclin A (A1 and A2), cyclin B1, cyclin D1, cyclin E1, and CDC6 were associated with YBX1 in ovarian cancer (Fig. 3A). In addition, we also searched other genes associated with YBX1 based on RNA-seq data from a cohort of patients with HGSC (TCGA). The results showed that YBX1 expression was closely correlated with the expression of cell proliferation-, cell division-, and DNA replication-related genes (Supplementary Figure S5A). Of these genes, the top correlated gene was CDC20 (Supplementary Figure S5B). We further selected CDC20 as a gene associated with YBX1 and the cell cycle, in addition to the above 6 cell cycle-related genes. The YBX1 gene was amplified in 8% of HGSC cases, and the CDC20 gene, which was localized at 1p34.2 (approximately 800 kb away from YBX1), was amplified in 7% of HGSC cases (Supplementary Figure S5C), suggesting that the close association of YBX1 and CDC20 was in part related to co-amplification of both genes in chromosome 1 in cases of HGSC. By contrast, the other 5 genes related to the cell cycle were localized in other chromosomes (Fig. 3A).Fig. 3 Effects of YBX1 siRNA on the expression levels of YBX1, cyclin A1, cyclin A2, cyclin B1, cyclin D1, cyclin E1, CDC6, and CDC20 mRNAs in ovarian cancer cell lines. (A) The eight selected genes are listed. Correlations of YBX1 with other genes are presented according to Spearman scores based on gene ontology analysis (TCGA database, n = 316) of HGSC, and the chromosomal locations of the 8 genes are indicated. The right panel of the illustrated model shows the sites of action of 7 cell cycle-related genes in the cell cycle. (B) RT-qPCR analysis showing mRNA expression levels of cell cycle-related genes in ovarian cancer cells. Student’s t-tests were used to compare differences between YBX1 siRNA#1-transfection groups and the control group. *p < 0.05; **p < 0.01. Error bars indicate standard deviations for 3 independent experiments. (C) RT-qPCR analysis showing mRNA expression levels of 7 genes in ovarian cancer cell lines following transfection with YBX1 siRNA#1 for 3 days. Expression levels were expressed as ratios relative to the expression in the corresponding negative control based on 3 independent assays. Student’s t-tests were used to compare differences between YBX1 siRNA#1-transfection groups and the control group. *p < 0.05; **p < 0.01. Error bars indicate standard deviations for 3 independent experiments. A heatmap plot of cell cycle-related genes from the comparison of the YBX1 siRNA#1-transfection group and the control group was presented. High expression levels in the YBX1 siRNA#1-transfection group are indicated in red, and low expression levels are indicated in blue. (D) JHOC-5 cells were transfected with luciferase reporter constructs containing the 1166 bp 5′-flanking region of the cyclin A1 gene with YBX1 siRNA#1 for 2 days. The firefly luciferase activity was normalized to the Renilla luciferase activity. Student’s t-tests were used to compare differences between YBX1 siRNA#1-transfection groups and the control group. **p < 0.01. Error bars indicate standard deviations for 3 independent experiments. (E) Schematic representation of potential YBX1 binding sites (Black boxes) and primer locations (arrows) used for ChIP assay in the promoter region of Cyclin A1 gene. (F) The YBX1 binding to the cyclin A1 promoter by ChIP assay in JHOC-5 cells.

The expression levels of cyclin A1 and cyclin E1 were highly variable among the 12 cell lines, and those of cyclin A2, cyclin B1, cyclin D1, CDC6, and CDC20 showed approximately fivefold differences in expression (Fig. 3B). Among the 7 genes tested in this analysis, cyclin A1, but not cyclin A2, was downregulated in all cell lines in group A, and only slightly downregulated if at all, in cell lines in group B following transfection with YBX1 siRNA#1 (Fig. 3C). Cyclin D1 expression was moderately reduced in 7 of the 9 cell lines in groups A and B, but not at all in group C cell lines (Fig. 3C). Together, these findings demonstrated that YBX1 knockdown suppressed cyclin A1 expression and moderately suppressed cyclin D1 expression in group A and B cell lines, but had little effect on the expression of cell cycle-related genes in group C cell lines.

We further confirmed the differential effects of YBX1 silencing by YBX1 siRNA#1 on cell growth and the expression of cell cycle-related genes using YBX1 siRNA#3. Consistent with YBX1 siRNA#1 transfection studies, transfection with YBX1 siRNA#3 induced growth inhibition in cell lines in groups A and B (Supplementary Figure S6A and B). However, there was no inhibition of cell growth in 3 cell lines in group C following transfection with YBX1 siRNA#3 (Supplementary Figure S6C). Furthermore, transfection with YBX1 siRNA#3 induced G2/M arrest in 4 cell lines in groups A and B, and reduced S phase population in 5 cell lines in group A (Supplementary Figure S6D–G). Among the 7 cell cycle-related genes, cyclin A1 was most markedly downregulated in 8 cell lines in groups A and B, while the expression levels of other genes were only slightly reduced, if at all, in a few cell lines of groups A and B (Supplementary Figure S7), consistent with our data for transfection with YBX1 siRNA#1.

To investigate whether YBX1 induces transcriptional activation of the cyclin A1 gene directly, we carried out luciferase assay and ChIP assay. Luciferase assay revealed that cyclin A1 promoter activity was downregulated by transfection with YBX1 siRNA in JHOC-5, SK-OV-3, but not in OVSAHO (Fig. 3D, Supplementary Figure S8A). Putative Y-box-like elements were located in the 5′-flanking region of the cyclin A1 gene (Fig. 3E). We also analyzed the binding of YBX1 to the promoter of the cyclin A1 gene by ChIP assay. The ChIP assay confirmed that YBX1 directly interacted with the 5′-flanking region of the cyclin A1 gene in JHOC-5, OVTOKO, but not in OVSAHO (Fig. 3F, Supplementary Figure S8B). These results suggest that YBX1 transcriptionally regulates cyclin A1 expression, except for group C cells.

Suppressive effect of YBX1 silencing on protein expression of cyclin A1

We next examined the effects of YBX1 silencing on the expression of cell cycle-related genes, cyclin A1, cyclin B1, cyclin D1, cyclin E1, CDC6, and CDC20 by western blot analysis, and found that YBX1 silencing markedly decreased cyclin A1 (Fig. 4). All 12 cell lines showed various levels of protein expression for 6 cell cycle-related genes. In particular, the protein expression levels of cyclin A1, cyclin D1, and cyclin E1 were highly variable among the cell lines (Fig. 4A), consistent with the observed mRNA levels of these genes (Fig. 3B). Almost all cell lines in groups A and B showed apparent reductions in cyclin A1 expression, when treated with YBX1 siRNA#1 or #3, but not in group C cell lines (Fig. 4B). There was a reduction in expression of cyclin A1 only in OVISE cells of group C by YBX1 siRNA#3, but its underlying mechanism remains unclear.Fig. 4 Effects of YBX1 knockdown by siRNA#1 and siRNA#3 on protein expression of cell cycle-related genes. (A) Expression of cell cycle-related genes as assessed by western blot analysis. (B) Effects of YBX1 siRNAs (siRNA#1 and siRNA#3) on the expression of cell cycle-related genes in cell lines following transfection with YBX1 siRNAs for 3 days. α-tubulin was used as a loading control.

Suppressive effect of cyclin A1 and A2 silencing on cell growth and the cell cycle

Among the cell cycle-related genes analyzed in this study, cyclin A1 was found to be the most susceptible to YBX1 silencing, suggesting the close regulatory relationship between cyclin A1 and YBX1 expression. We further examined whether cyclin A1 silencing induced distinct effects on cell growth and cell cycle arrest in cancer cell lines. We showed that silencing of cyclin A1 induced cell growth inhibition and G2/M arrest in group A and B cells in Fig. 5. Cyclin A1 silencing using specific siRNA induced growth inhibition of cell lines in groups A and B but no inhibition of group C cell lines (Fig. 5A and Supplementary Figure S9A). Additionally, FACS analysis showed that cyclin A1 silencing caused G2/M phase arrest in 4 of 9 cell lines in groups A and B (Fig. 5B, C, and D, and Supplementary Figure S9B). By contrast, no G2/M arrest was observed in all group C cell lines. Thus, cyclin A1 and YBX1 promoted the G2/M phase in group A and B cell lines.Fig. 5 Effects of cyclin A1 knockdown by cyclin A1 siRNA on cell growth, and the expression levels of YBX1 and cell cycle-related genes in HGSC and OCCC tumors. (A) Cell growth of ovarian cancer cell lines on days 1, 3, and 5 after transfection with cyclin A1 siRNA. Student’s t-tests were used to compare differences between control- and cyclin A1 siRNA-transfected cells. *p < 0.05; **p < 0.01. Error bars indicate standard deviations for 3 independent experiments. (B–D) Percentages of cells in G0/G1 (B), S (C), and G2/M (D) phases following transfection with cyclin A1 siRNA for 3 days. Percentages were determined by gating the FACS plot. Student’s t-tests were used to compare differences between control- and cyclin A1 siRNA-transfected cells. *p < 0.05; **p < 0.01. Error bars indicate standard deviations for 3 independent experiments. (E) Expression levels of YBX1 and cyclin A1, as assessed by RT-qPCR analysis in HGSC (n = 50) and OCCC tumors (n = 51). The statistical significance was determined using the Mann–Whitney U tests. (F, G) Correlation of YBX1 mRNA expression levels with the mRNA expression of cyclin A1 in HGSC (n = 50) (F) and OCCC tumors (n = 51) (G). The statistical significance of the correlations was determined using Pearson’s correlation coefficients and p values.

Cyclin A2 is also known to play a key role in G2/M transition and progression43. We next examined whether cyclin A2 silencing induced distinct effects on cell growth and cell cycle in ovarian cancer cell lines (Supplementary Figure S10A–F). Cyclin A2 silencing induced growth inhibition and cell cycle arrest at G2/M in almost all cell lines in groups A, B, and C (Supplementary Figure S10B and F). These results indicated that both cyclin A1 and cyclin A2 regulate the G2/M phase, but cyclin A1 is specifically involved in the G2/M phase transition controlled by YBX1 in ovarian cancer. It is suggested that cyclin A1 plays an important role in proliferation promoted by YBX1.

YBX1 expression correlates with cyclin A1 expression in HGSC samples

We analyzed mRNA expression levels of YBX1 and cyclin A1 genes in HGSC and OCCC specimens (Fig. 5E). HGSC tumors (n = 50) showed significantly (p = 0.0053) higher YBX1 mRNA levels than OCCC tumors (n = 51). The expression level of cyclin A1 (p < 0.0001) was significantly higher in HGSC samples than in OCCC samples.

We finally assessed whether the expression level of cyclin A1 was associated with that of YBX1 in tumor specimens of HGSC (Fig. 5F) and OCCC (Fig. 5G). In HGSC specimens, YBX1 mRNA levels were significantly (p < 0.0001) correlated with the mRNA levels of cyclin A1 (Fig. 5F). By contrast, YBX1 levels were not correlated with cyclin A1 levels in OCCC specimens (Fig. 5G). Together, YBX1 expression level was high and correlated with the expression level of cyclin A1 in HGSC tumors, but not in OCCC tumors.

Discussion

In our current study, among the 12 ovarian cancer cell lines, YBX1 silencing induced growth inhibition in 9 cell lines (groups A and B), and no growth inhibition in 3 cell lines (group C). Furthermore, SU056, a YBX1 inhibitor, also suppressed cell growth of group A cell lines more strongly than group C, except for one cell line, OVISE (Supplementary Table S2). All cell lines in group A and two cell lines in group B showed G2/M phase arrest and reduced S phase populations following transfection with YBX1 siRNAs (Table 1). By contrast, the cell cycle distributions in group C cell lines were not at all affected by YBX1 silencing. Thus, these findings indicated that the growth of ovarian cancer cell lines could be dependent or independent of YBX1 in close association with the specific cell cycle phases (Table 1). Table 1 Classification of ovarian cancer cell lines into 3 groups based on cell growth dependence on YBX1.

Group	Cell line	Cell growth suppression1,2)	Cell cycle arrest3)	
siYBX1 #1	siYBX1#3	siCyclinA1	siCyclinA2	siYBX1#1	siYBX1#3	siCyclinA1	siCyclinA2	
A	ES2	+  + 	+  + 	+ 	+  + 	G2/M	G2/M	G2/M	G2/M	
JHOC-5	+  + 	+  + 	+  + 	+  + 	G2/M	G1	G2/M	S, G2/M	
MCAS	+  + 	+ 	+ 	+  + 	G2/M	G2/M	NC	S, G2/M	
OVTOKO	+  + 	+  + 	+ 	+  + 	G2/M	G1	G2/M	G2/M	
B	OVCAR3	+ 	+ 	+ 	+  + 	G2/M	G2/M	G2/M	G2/M	
TOV-112D	+ 	+ 	+ 	+  + 	S	G1, G2/M	NC	S, G2/M	
TOV-21G	+ 	+ 	+ 	+ 	NC	NC	NC	S, G2/M	
SK-OV-3	+ 	+ 	+ 	+  + 	NC	NC	NC	S, G2/M	
KOC-7C	+ 	+ 	+ 	+ 	NC	NC	NC	S	
C	OVSAHO	± 	± 	± 	+ 	NC	NC	NC	S, G2/M	
OVISE	± 	± 	± 	+  + 	NC	NC	NC	G2/M	
OVMANA	± 	± 	± 	+ 	NC	NC	NC	G2/M	
1) Survival rato of siRNAs-treated cell lines to siCtl-treated cell lines on day 5 after siRNAs treatment.

2) The effect on growth inhibition compared to the control group on day 5 was calculated and expressed as follows: +  + : > 50%; + : > 10%; ± : < 10%

3) Phases with significantly increased population in the cell lines after 72 h of siRNA treatment compared to the siCtl-treated cell lines; NC: No change of cell cycle phases by transfected siRNA.

Previous studies reported that the high expression of YBX1 is associated with cisplatin and paclitaxel resistance in ovarian cancer31,32. In our present study, however, the sensitivity to cisplatin and paclitaxel was not appreciably different among all cell lines of groups A, B, and C (Supplementary Table S2). Since there was no marked difference in the expression levels of YBX1 among the cell lines in groups A, B, and C (Fig. 1C), YBX1-induced drug resistance to cisplatin or paclitaxel and YBX1-dependence on cell proliferation might be mediated through different mechanisms in cancer cells. Concerning the cell cycle arrest at G2/M phase by YBX1 silencing, Ban and colleagues reported that YBX1 is overexpressed in nasopharyngeal cancer, and also that high expression of YBX1 positively associates with expression of G2/M checkpoint-related genes, resulting in promotion of cancer cell growth44. Mehta et al. reported that phosphorylated YBX1 enters the nucleus in G2/M phase45. Jürchott et al. previously reported that cyclin A2 and cyclin B1 expression plays key roles in promoting G2/M phase progression via YBX1 through its interaction with the Y-box in its regulatory promoter region19. Furthermore, Cybulski et al. also demonstrated that cyclin A2 expression is correlated with YBX1 expression in ovarian cancer33. Rivera et al. previously reported that cyclin A1 is associated with apoptosis, G2/M arrest, and mitotic catastrophe in ovarian cancer cells46. These studies suggest that YBX1 plays key roles in cell growth promotion and transcription of cell cycle-related genes at G2/M phase, consistent with our present study.

In this study, we first found that cyclin A1 expression was most prominently suppressed by YBX1 knockdown in group A and B cell lines (Figs. 3 and 4). Moreover, cell growth inhibition and cell cycle arrest at G2/M phase were induced by cyclin A1 silencing in group A and B cell lines (Fig. 5). YBX1-dependent cell growth and G2/M transition could be spurred in the close collaboration with cyclin A1 (Table 1). On the other hand, cell growth inhibition by G2/M arrest was observed by cyclin A2 silencing in all group A, B, and C cell lines (Table 1 and Supplementary Figure S10). Cyclin A2 silencing markedly induced cell cycle arrest at S and G2/M phases (Supplementary Figure S10). Although the expression of cyclin A2 was not at all affected by YBX1 silencing (Fig. 3), cyclin A2 also plays an important role in cell growth and cell cycle promotion in ovarian cancer cell. Previous studies demonstrated that cyclin A2 plays a key role in tumor growth and progression by other human malignancies44,47,48. However, it has been reported that cyclinA1, but not cyclinA2, is involved in apoptosis in non-small cell lung cancer cells46, and that the Cyclin A1/CDK1 complex phosphorylates Rb and p53 more strongly than the Cyclin A2/CDK1 complex49. These studies suggest that cyclin A1 and cyclin A2 play different roles in the cell cycle of various cancer cell lines. Furthermore, Ye et al. pointed out that since the oscillation in cyclin A1 protein levels during the cell cycle may blunt the prediction of response to therapeutic drugs, it is reasonable to explore the regulatory mechanisms of cyclin expression to identify cyclin regulators that are constantly expressed50. Understanding the mechanism of cell proliferation by cyclin A1 via constitutively expressed YBX1 may provide a specific therapy for ovarian cancer.

The cell growth dependence on YBX1 may be attributable to whether YBX1 could promote cyclin A1 gene expression during G2/M phase. In group A and B cells, YBX1 induced the cyclin A1 promoter activity (Fig. 3D and F). While transcriptional activation of cyclin A1 by YBX1 occurs in group A cells, this transcriptional activation does not appear in group C cells, suggesting that YBX1 exerts its function only in group A and B cells. YBX1 phosphorylation and nuclear translocation induce transcriptional activation of YBX1, and PKCα has the ability to phosphorylate YBX1 at S10227,42. We demonstrated that the expression and phosphorylation of PKCα were higher in group A cell lines than in group C cell lines (Supplementary Figure S3A). Activation of PKCα downregulates cyclinA1 expression and induces G2/M arrest in lung cancer cells51. In this study, there was no difference in YBX1 phosphorylation and nuclear localization between group A and group C cell lines (Fig. 1C and Supplementary Figure S3B). Phosphorylation of YBX1 at S102 by PKCα may not be associated with YBX1-dependent proliferation in ovarian cancer cells. However, these studies suggest that the close association between PKCα and YBX1 may affect the promotion of cyclin A1 expression and cell proliferation by YBX1. Further study should be required to understand how the expression of cyclin A1 and cyclin A2 could be differentially regulated in correlation with YBX1 on a molecular basis. We demonstrated higher expression of YBX1 and cyclin A1 in HGSC than in OCCC tumors and correlation of YBX1 and cyclin A1 in HGSC, not in OCCC tumors. However, we could not observe any difference in the effects of YBX1 on the cyclin A1 expression between HGSC-derived and OCCC-derived cancer cells in vitro. Some cell lines have been reported to have mutations and mRNA expression profiles that differ from tumor samples from HGSC and OCCC patients52. It has been pointed out that SK-OV-3 is widely considered to be a good model for HGSC although no histological subtype was specified52, and ES2 cells, reportedly derived from OCCC, appeared more like HGSC than OCCC53. In the current study, we classified ES2 cells as HGSC. Since the actual origin of the above cell lines is not clear, further studies with cells of determined origin are required to distinguish the function of YBX1 in HGSCs and OCCC in vitro.

Expression of cyclin E1 as well as cyclin A2 was not affected by YBX1 silencing in ovarian cancer cells (Figs. 3C and 4). Three cell lines in group C showed the highest expression levels of cyclin E1 among all cell lines (Fig. 4A). RPPA analysis also showed increased protein expression levels of cyclin E1 in these three cell lines as compared to cell lines in group A (Supplementary Table S3). It has been reported that enhanced expression of cyclin E1 is associated with poor outcomes in patients with ovarian cancer54,55. Although YBX1 is not involved in cyclin E1 expression in ovarian cancer cells in this study, enhanced cyclin E1 mRNA expression may facilitate ovarian tumor growth and progression independent of YBX1.

YBX1 is associated with tumor progression in ovarian tumors, and targeting YBX1 and its activation pathway may contribute to the further development of anticancer therapeutics15,16,27. Our findings supported that YBX1 played pivotal roles in cell growth promotion in ovarian cancer cells, and also that this cell growth dependence on YBX1 is attributable to the promotion of G2/M transition in collaboration with cyclin A1 but not cyclin A2. However, we could not clarify the key proteins that predict cell growth dependence on YBX1. Further study should be required to understand the mechanisms underlying how YBX1 could promote ovarian cancer growth through elucidation of the association between YBX1 and cyclin A1 on a molecular basis. In addition, we did not investigate whether YBX1-dependent proliferation is associated with malignant progression, such as tumor growth using an animal model. The results from in vitro experiments may not fully reflect the biological behavior of cells in vivo. Future studies in animal models and clinical samples are needed to validate our findings and to understand the role of YBX1-dependent growth in malignant tumor progression and tumor growth in vivo. Identification of cell cycle regulatory targets associated with YBX1 in ovarian cancer may provide novel insights to facilitate the development of cancer therapy targeting YBX1.

Supplementary Information

Supplementary Figures.

Supplementary Table 1.

Supplementary Table 2.

Supplementary Table 3.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72174-9.

Acknowledgements

We thank Yoshio Ide, president of St. Mary’s Hospital, for his continuous encouragements of our present study.

Author contributions

Y. M., D. K., T. M., T. Shibata., M. O., and M. K. conceived and designed the experiments. Y. M., D. K., T. M., T. Shibata, A. K, and K. Kanazawa. performed the experiments. A. K., J. A., N. Y., A. O., H. I., T. Sugiyama, A. T., S. N., N. T., and K. Kato contributed reagents/materials/analysis tools. Y. M, D. K., T. M., M. O. and M. K. wrote and edited the paper. All authors reviewed the manuscript.

Funding

This research was supported by JSPS KAKENHI Grant Number, 24K09909 to Y.M.

Data availability

The data generated in the present study may be found in Gene Expression Omnibus (GEO) at GDS3297.

Competing interests

The authors declare no competing interests.

Ethical approval and consent to participate

This study was approved by the institutional review board at each hospital (Kyushu University, # 622-00; The Jikei University school of Medicine, 32–379 (10467)). This study conforms to the principles of the Declaration of Helsinki and informed consent was obtained from all patients.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These author contributed equally: Yuichi Murakami and Daisuke Katsuchi.
==== Refs
References

1. Otto T Sicinski P Cell cycle proteins as promising targets in cancer therapy Nat. Rev. Cancer 2017 17 93 115 10.1038/nrc.2016.138 28127048
Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93–115 (2017).28127048
2. Batra A Winquist E Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer Expert Opin. Emerg. Drugs 2018 23 271 282 10.1080/14728214.2018.1547707 30422005
Batra, A. & Winquist, E. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opin. Emerg. Drugs 23, 271–282 (2018).30422005
3. Dall’Acqua A Inhibition of CDK4/6 as therapeutic approach for ovarian cancer patients: Current evidences and future perspectives Cancers (Basel) 2021 13 1 20 10.3390/cancers13123035
Dall’Acqua, A. et al. Inhibition of CDK4/6 as therapeutic approach for ovarian cancer patients: Current evidences and future perspectives. Cancers (Basel) 13, 1–20 (2021).
4. Bai S Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer Mol. Cancer Ther. 2022 21 1473 1484 10.1158/1535-7163.MCT-21-0873 35732503
Bai, S. et al. Targeting therapeutic resistance and multinucleate giant cells in CCNE1-amplified HR-proficient ovarian cancer. Mol. Cancer Ther. 21, 1473–1484 (2022).35732503
5. Kohno K Izumi H Uchiumi T Ashizuka M Kuwano M The pleiotropic functions of the Y-box-binding protein, YB-1 BioEssays 2003 25 691 698 10.1002/bies.10300 12815724
Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M. & Kuwano, M. The pleiotropic functions of the Y-box-binding protein, YB-1. BioEssays 25, 691–698 (2003).12815724
6. Fukuda T Characterization of the 5’-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein Nucleic Acids Res. 2004 32 611 622 10.1093/nar/gkh223 14752049
Fukuda, T. et al. Characterization of the 5’-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein. Nucleic Acids Res. 32, 611–622 (2004).14752049
7. Bergmann S YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification Cancer Res. 2005 65 4078 4087 10.1158/0008-5472.CAN-04-4056 15899797
Bergmann, S. et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 65, 4078–4087 (2005).15899797
8. Davies AH YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer Stem Cells 2014 32 1437 1450 10.1002/stem.1707 24648416
Davies, A. H. et al. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells 32, 1437–1450 (2014).24648416
9. Fujii T Expression of HER2 and estrogen receptor α depends upon nuclear localization of Y-box binding protein-1 in human breast cancers Cancer Res. 2008 68 1504 1512 10.1158/0008-5472.CAN-07-2362 18316615
Fujii, T. et al. Expression of HER2 and estrogen receptor α depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 68, 1504–1512 (2008).18316615
10. Imada K Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression Clin. Cancer Res. 2013 19 4638 4650 10.1158/1078-0432.CCR-12-3705 23838318
Imada, K. et al. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin. Cancer Res. 19, 4638–4650 (2013).23838318
11. Yan X High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer Int. J. Clin. Exp. Pathol. 2014 7 8715 8723 25674237
Yan, X. et al. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. Int. J. Clin. Exp. Pathol. 7, 8715–8723 (2014).25674237
12. Janz M Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1 Int. J. Cancer 2002 97 278 282 10.1002/ijc.1610 11774277
Janz, M. et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97, 278–282 (2002).11774277
13. Basaki Y Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells Oncogene 2007 26 2736 2746 10.1038/sj.onc.1210084 17072343
Basaki, Y. et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26, 2736–2746 (2007).17072343
14. Basaki Y Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells Eur. J. Cancer 2010 46 954 965 10.1016/j.ejca.2009.12.024 20079629
Basaki, Y. et al. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells. Eur. J. Cancer 46, 954–965 (2010).20079629
15. Kosnopfel C Sinnberg T Schittek B Y-box binding protein 1-A prognostic marker and target in tumour therapy Eur. J. Cell Biol. 2014 93 61 70 10.1016/j.ejcb.2013.11.007 24461929
Kosnopfel, C., Sinnberg, T. & Schittek, B. Y-box binding protein 1-A prognostic marker and target in tumour therapy. Eur. J. Cell Biol. 93, 61–70 (2014).24461929
16. Maurya PK Role of Y box protein-1 in cancer: As potential biomarker and novel therapeutic target J. Cancer 2017 8 1900 1907 10.7150/jca.17689 28819388
Maurya, P. K. et al. Role of Y box protein-1 in cancer: As potential biomarker and novel therapeutic target. J. Cancer 8, 1900–1907 (2017).28819388
17. Shibata T Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression Cancer Res. 2017 77 545 556 10.1158/0008-5472.CAN-16-1593 27879270
Shibata, T. et al. Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression. Cancer Res. 77, 545–556 (2017).27879270
18. Johnson TG YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms Cancers (Basel) 2020 12 2285 10.3390/cancers12082285 32823952
Johnson, T. G. et al. YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms. Cancers (Basel) 12, 2285 (2020).32823952
19. Jürchott K YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression J. Biol. Chem. 2003 278 27988 27996 10.1074/jbc.M212966200 12695516
Jürchott, K. et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J. Biol. Chem. 278, 27988–27996 (2003).12695516
20. Chatterjee M The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma Blood 2008 111 3714 3722 10.1182/blood-2007-05-089151 18006704
Chatterjee, M. et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 111, 3714–3722 (2008).18006704
21. Fujiwara-Okada Y Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma Br. J. Cancer 2013 108 836 847 10.1038/bjc.2012.579 23462806
Fujiwara-Okada, Y. et al. Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br. J. Cancer 108, 836–847 (2013).23462806
22. Harada M YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers Genes Cells 2014 19 504 516 10.1111/gtc.12150 24774443
Harada, M. et al. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers. Genes Cells 19, 504–516 (2014).24774443
23. Liu Y lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer Sci. Rep. 2015 5 10159 10.1038/srep10159 25959498
Liu, Y. et al. lncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Sci. Rep. 5, 10159 (2015).25959498
24. Miao X Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma Exp. Cell Res. 2016 346 157 166 10.1016/j.yexcr.2016.07.003 27397581
Miao, X. et al. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp. Cell Res. 346, 157–166 (2016).27397581
25. Khandelwal P Padala MK Cox J Guntaka RV The N-terminal domain of Y-box binding protein-1 induces cell cycle arrest in G2/M phase by binding to cyclin D1 Int. J. Cell Biol. 2009 2009 243532 10.1155/2009/243532 20414334
Khandelwal, P., Padala, M. K., Cox, J. & Guntaka, R. V. The N-terminal domain of Y-box binding protein-1 induces cell cycle arrest in G2/M phase by binding to cyclin D1. Int. J. Cell Biol. 2009, 243532 (2009).20414334
26. Kotake Y Arikawa N Tahara K Maru H Naemura M Y-box binding protein 1 is involved in regulating the G2/M phase of the cell cycle Anticancer Res. 2017 37 1603 1608 10.21873/anticanres.11490 28373420
Kotake, Y., Arikawa, N., Tahara, K., Maru, H. & Naemura, M. Y-box binding protein 1 is involved in regulating the G2/M phase of the cell cycle. Anticancer Res. 37, 1603–1608 (2017).28373420
27. Kuwano M Shibata T Watari K Ono M Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer Cancer Sci. 2019 110 1536 1543 10.1111/cas.14006 30903644
Kuwano, M., Shibata, T., Watari, K. & Ono, M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 110, 1536–1543 (2019).30903644
28. Kamura T Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999 85 2450 2454 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U 10357417
Kamura, T. et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?. Cancer 85, 2450–2454 (1999).10357417
29. Huang X Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer Gynecol. Oncol. 2004 93 287 291 10.1016/j.ygyno.2004.01.040 15099935
Huang, X. et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol. Oncol. 93, 287–291 (2004).15099935
30. Oda Y Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt LRP/MVP and P-glycoprotein expression Cancer Sci. 2007 98 1020 1026 10.1111/j.1349-7006.2007.00492.x 17459055
Oda, Y. et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt LRP/MVP and P-glycoprotein expression. Cancer Sci. 98, 1020–1026 (2007).17459055
31. Yahata H Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer J. Cancer Res. Clin. Oncol. 2002 128 621 626 10.1007/s00432-002-0386-6 12458343
Yahata, H. et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J. Cancer Res. Clin. Oncol. 128, 621–626 (2002).12458343
32. Kang Y Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer J. Natl. Cancer Inst. 2013 105 1485 1495 10.1093/jnci/djt210 24062525
Kang, Y. et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J. Natl. Cancer Inst. 105, 1485–1495 (2013).24062525
33. Cybulski M Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer Anticancer Res. 2015 35 1715 1722 25750333
Cybulski, M. et al. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer. Anticancer Res. 35, 1715–1722 (2015).25750333
34. Panupinthu N Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer Oncogene 2014 33 2846 2856 10.1038/onc.2013.259 23851501
Panupinthu, N. et al. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene 33, 2846–2856 (2014).23851501
35. Tailor D Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer Cell Chem. Biol. 2021 28 1206 1220 10.1016/j.chembiol.2021.02.014 33713600
Tailor, D. et al. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem. Biol. 28, 1206–1220 (2021).33713600
36. Shibata T Targeting phosphorylation of Y-box–binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance Mol. Cancer Ther. 2020 19 882 894 10.1158/1535-7163.MCT-19-0690 31879363
Shibata, T. et al. Targeting phosphorylation of Y-box–binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance. Mol. Cancer Ther. 19, 882–894 (2020).31879363
37. Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25, 402–408 (2001).11846609
38. Shibata T Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells Mol. Cancer Ther. 2013 12 737 746 10.1158/1535-7163.MCT-12-1125 23445612
Shibata, T. et al. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol. Cancer Ther. 12, 737–746 (2013).23445612
39. Bell D Integrated genomic analyses of ovarian carcinoma Nature 2011 474 609 615 10.1038/nature10166 21720365
Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).21720365
40. Etemadmoghadam D Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer PLoS One 2010 5 e15498 10.1371/journal.pone.0015498 21103391
Etemadmoghadam, D. et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 5, e15498 (2010).21103391
41. Li J Characterization of human cancer cell lines by reverse-phase protein arrays Cancer Cell 2017 31 225 239 10.1016/j.ccell.2017.01.005 28196595
Li, J. et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31, 225–239 (2017).28196595
42. Stratford AL Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells Breast Cancer Res. 2008 10 1 12 10.1186/bcr2202
Stratford, A. L. et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 10, 1–12 (2008).
43. Gong D Ferrell JE The roles of cyclin A2, B1, and B2 in early and late mitotic events Mol. Biol. Cell 2010 21 3149 3161 10.1091/mbc.e10-05-0393 20660152
Gong, D. & Ferrell, J. E. The roles of cyclin A2, B1, and B2 in early and late mitotic events. Mol. Biol. Cell 21, 3149–3161 (2010).20660152
44. Ban Y RNA-binding protein YBX1 promotes cell proliferation and invasiveness of nasopharyngeal carcinoma cells via binding to AURKA mRNA J. Cancer 2021 12 3315 3324 10.7150/jca.56262 33976741
Ban, Y. et al. RNA-binding protein YBX1 promotes cell proliferation and invasiveness of nasopharyngeal carcinoma cells via binding to AURKA mRNA. J. Cancer 12, 3315–3324 (2021).33976741
45. Mehta S Dephosphorylation of YB-1 is required for nuclear localisation during G2 phase of the cell cycle Cancers (Basel). 2020 12 1 21 10.3390/cancers12020315
Mehta, S. et al. Dephosphorylation of YB-1 is required for nuclear localisation during G2 phase of the cell cycle. Cancers (Basel). 12, 1–21 (2020).
46. Rivera A Mavila A Bayless KJ Davis GE Maxwell SA Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells Cell. Mol. Life Sci. 2006 63 1425 1439 10.1007/s00018-006-5521-5 16799873
Rivera, A., Mavila, A., Bayless, K. J., Davis, G. E. & Maxwell, S. A. Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells. Cell. Mol. Life Sci. 63, 1425–1439 (2006).16799873
47. Handa K Yamakawa M Takeda H Kimura S Takahashi T Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin a as an indicator of poor prognosis Int. J. cancer 1999 84 225 233 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A 10371338
Handa, K., Yamakawa, M., Takeda, H., Kimura, S. & Takahashi, T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin a as an indicator of poor prognosis. Int. J. cancer 84, 225–233 (1999).10371338
48. Bukholm IRK Bukholm G Nesland JM Over-expression of cyclin a is highly associated with early relapse and reduced survival in patients with primary breast carcinomas Int. J. Cancer 2001 93 283 287 10.1002/ijc.1311 11410878
Bukholm, I. R. K., Bukholm, G. & Nesland, J. M. Over-expression of cyclin a is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int. J. Cancer 93, 283–287 (2001).11410878
49. Joshi AR Jobanputra V Lele KM Wolgemuth DJ Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2 Biochem. Biophys. Res. Commun. 2009 378 595 599 10.1016/j.bbrc.2008.11.077 19056339
Joshi, A. R., Jobanputra, V., Lele, K. M. & Wolgemuth, D. J. Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2. Biochem. Biophys. Res. Commun. 378, 595–599 (2009).19056339
50. Ye H PICH activates Cyclin A1 transcription to drive S-phase progression and chemoresistance in gastric cancer Cancer Res. 2023 83 3767 3782 10.1158/0008-5472.CAN-23-1331 37646571
Ye, H. et al. PICH activates Cyclin A1 transcription to drive S-phase progression and chemoresistance in gastric cancer. Cancer Res. 83, 3767–3782 (2023).37646571
51. Oliva JL Caino MC Senderowicz AM Kazanietz MG S-phase-specific activation of PKCα induces senescence in non-small cell lung cancer cells J. Biol. Chem. 2008 283 5466 5476 10.1074/jbc.M707576200 18162471
Oliva, J. L., Caino, M. C., Senderowicz, A. M. & Kazanietz, M. G. S-phase-specific activation of PKCα induces senescence in non-small cell lung cancer cells. J. Biol. Chem. 283, 5466–5476 (2008).18162471
52. Domcke S Sinha R Levine DA Sander C Schultz N Evaluating cell lines as tumour models by comparison of genomic profiles Nat. Commun. 2013 4 2126 10.1038/ncomms3126 23839242
Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).23839242
53. Kwok ALM Caution over use of ES2 as a model of ovarian clear cell carcinoma J. Clin. Pathol. 2014 67 921 922 10.1136/jclinpath-2014-202430 25049276
Kwok, A. L. M. et al. Caution over use of ES2 as a model of ovarian clear cell carcinoma. J. Clin. Pathol. 67, 921–922 (2014).25049276
54. Rosen DG Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma Cancer 2006 106 1925 1932 10.1002/cncr.21767 16568440
Rosen, D. G. et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106, 1925–1932 (2006).16568440
55. Kang EY CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An ovarian tumor tissue analysis consortium study Cancer 2023 129 697 713 10.1002/cncr.34582 36572991
Kang, E. Y. et al. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An ovarian tumor tissue analysis consortium study. Cancer 129, 697–713 (2023).36572991
